{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"79"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"109"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}],"title":"Marginal response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"32"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"description":"Response was defined according to International Myeloma Working Group criteria (2006)\n\n* Complete Response: Complete disappearance of M-protein from serum \\& urine on immunofixation, normalization of Free Light Chain (FLC) ratio \\& \\<5% plasma cells in bone marrow (BM)\n* Partial Response: \\>= 50% reduction in serum M-Component and/or Urine M-Component \\>= 90% reduction or \\<200 mg per 24 hours; or \\>= 50% decrease in difference between involved and uninvolved FLC levels\n* Marginal Response: 25-49% reduction in serum M-component \\& urine M-component by 50-89% which still exceeds 200mg/24hour\n* Progressive Disease: Defined in primary outcome measure\n* Stable Disease: Not meeting any of the criteria above","groups":[{"description":"Beginning between day 100-110, patients receive oral lenalidomide once daily.","id":"OG000","title":"Lenalidomide Maintenance"},{"description":"Beginning between day 100-110, patients receive oral placebo once daily.\n\n(closed as of 12/17/09)","id":"OG001","title":"Placebo Maintenance"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Response to Autologous Hematopoietic Stem-cell Transplant (HSCT) at Day 100","type":"SECONDARY","unitOfMeasure":"participants"}